Evidence map›Paper›PMID 41477868›Full record

ArticleScience advances2026

Phenotypic discovery and therapeutic evaluation of an

Junghyeon Lee, Hyeryeon Jung, Eunhee G Kim, Jinsung Ahn, Michael C Haffner, Peter S Nelson, Kwang Pyo Kim, John K Lee, Eugene C Yi, Kristine M Kim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Junghyeon LeeDepartment of Systems Immunology, Division of Biomedical Convergence, College of Biomedical Science, Kangwon National University, Chuncheon 24341, Republic of Korea.ORCID 0009-0008-4229-7195
Hyeryeon JungDepartment of Systems Immunology, Division of Biomedical Convergence, College of Biomedical Science, Kangwon National University, Chuncheon 24341, Republic of Korea.ORCID 0000-0001-5179-8604
Eunhee G KimDepartment of Systems Immunology, Division of Biomedical Convergence, College of Biomedical Science, Kangwon National University, Chuncheon 24341, Republic of Korea.ORCID 0009-0003-9931-1000
Jinsung AhnDepartment of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080, Republic of Korea.ORCID 0009-0007-9616-2918
Michael C HaffnerDivision of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0003-0809-6425
Peter S NelsonDivision of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0002-5451-5726
Kwang Pyo KimDepartment of Applied Chemistry, Department of Applied Chemistry, Institute of Natural Science, Kyung Hee University, Yongin, Republic of Korea.ORCID 0000-0003-0095-3787
John K LeeDivision of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0002-6570-2180
Eugene C YiDepartment of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080, Republic of Korea.ORCID 0000-0002-0615-7397
Kristine M KimDepartment of Systems Immunology, Division of Biomedical Convergence, College of Biomedical Science, Kangwon National University, Chuncheon 24341, Republic of Korea.ORCID 0000-0002-1133-0668

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-drug conjugates (ADCs) require antibodies with both high specificity and efficient internalization, features often overlooked by conventional discovery pipelines that rely on preselected antigens and recombinant proteins. Here, we describe an integrated phenotypic platform that combines target-unbiased live-cell biopanning with in situ chemical cross-linking and mass spectrometry to concurrently identify internalizing antibodies and their membrane-bound cognate antigens in a native cellular context. Using this approach, we identified 2E7, an antibody with rapid internalization and specificity for the integrin α3β1 (

Indexed as

ImmunoconjugatesIntegrin alpha3beta1Urinary Bladder NeoplasmsAnimalsCell Line, TumorDrug DiscoveryHumansIntegrin alpha3MiceOligopeptidesPhenotypeProteomicsXenograft Model Antitumor AssaysImmunoconjugatesIntegrin alpha3Integrin alpha3beta1monomethyl auristatin EOligopeptides

Identifiers

PMID41477868
PMCPMC12757053

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.